[go: up one dir, main page]

AR045828A1 - Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa - Google Patents

Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa

Info

Publication number
AR045828A1
AR045828A1 ARP040103478A ARP040103478A AR045828A1 AR 045828 A1 AR045828 A1 AR 045828A1 AR P040103478 A ARP040103478 A AR P040103478A AR P040103478 A ARP040103478 A AR P040103478A AR 045828 A1 AR045828 A1 AR 045828A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
lower alkyl
alkyl
inhibitors
cycloheteroalkyl
Prior art date
Application number
ARP040103478A
Other languages
English (en)
Inventor
Saleem Ahmad
Jeffrey A Robl
Khehyong Ngu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR045828A1 publication Critical patent/AR045828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona compuestos que tienen la estructura, los cuales son inhibidores de HMG CoA reductasa y por consiguiente son activos en la inhibición de la biosíntesis del colesterol, la modulación de los lípidos en el suero de la sangre, por ejemplo, para reducir el colesterol de LDL y/o para incrementar el colesterol de HDL, y para tratar la hiperlipidemia, dislipidemia, terapia de reemplaza de hormonas, hipercolesterolemia, hipertrigliceridemia y ateroesclerosis así como la enfermedad de Alzheimer y la osteoporosis. Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque X es N o CR5; R1 y R2 son los mismos o diferentes y son seleccionados independientemente de H, alquilo, alcoxialquilo, arilalquilo, cicloalquilo, alquenilo, cicloalquenilo, arilo, heteroarilo o cicloheteroalquilo; R3 es arilo, heteroarilo, cicloalquilo, o cicloheteroalquilo; R4 es H, alquilo, cicloalquilo, haloalquilo, alcoxialquilo, alquiltioalquilo, alquilsulfonilo, arilsulfonilo, alcoxicarbonilo, ariloxicarbonilo, heteroariloxicarbonilo, alquilaminocarbonilo, arilaminocarbonilo, alquiltiocarbonilo, heteroarilaminocarbonilo, alquilaminosulfonilo, alquilcarbonilo, arilcarbonilo, heteroarilcarbonilo, o heteroarilsulfonilo; R5 es H o alquilo inferior; Z es un grupo de fórmulas (2); R6 es H, o alquilo inferior o un metal; R7 es H o alquilo inferior; y "líneas y puntos" representan un enlace sencillo o un doble enlace (el cual puede ser cis o trans); o una sal del mismo aceptable farmacéuticamente en donde R6 es H, o un éster del mismo, un éster de profármaco del mismo, y todos los estereoisómeros del mismo.
ARP040103478A 2003-09-25 2004-09-24 Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa AR045828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50589303P 2003-09-25 2003-09-25

Publications (1)

Publication Number Publication Date
AR045828A1 true AR045828A1 (es) 2005-11-16

Family

ID=34393081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103478A AR045828A1 (es) 2003-09-25 2004-09-24 Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa

Country Status (6)

Country Link
US (1) US7371759B2 (es)
EP (1) EP1667997A1 (es)
AR (1) AR045828A1 (es)
PE (1) PE20050958A1 (es)
TW (1) TW200522950A (es)
WO (1) WO2005030758A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US20060058283A1 (en) * 2004-09-15 2006-03-16 Zymes, Inc. Compositions comprising ubiquinones
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
AP2007004234A0 (en) * 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
GB0524427D0 (en) * 2005-11-30 2006-01-11 7Tm Pharma As Use of receptor ligands in threapy
CA2634833A1 (en) * 2005-12-29 2007-07-05 Novartis Ag Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
MX2008014284A (es) * 2006-05-10 2008-11-18 Novartis Ag Derivados biciclicos como inhibidores de cetp.
EP2018376A1 (en) * 2006-05-11 2009-01-28 Novartis Pharma AG Benzylamine derivatives as cetp inhibitors
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
EP2086961A1 (en) * 2006-11-15 2009-08-12 Novartis AG Heterocyclic derivatives as cetp inhibitors
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
AU2009326326B2 (en) * 2008-12-08 2015-05-21 F. Hoffmann-La Roche Ag Combined drug administration
CA2759385A1 (en) 2009-04-27 2010-11-04 Dow Agrosciences, Llc Insecticidal pyridine compounds
KR101157314B1 (ko) * 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
CN102219780B (zh) * 2010-04-14 2014-08-06 上海京新生物医药有限公司 制备(3r,5s,e)-7-(2-(n-甲基甲磺酰胺基)-4-(4-氟苯基)-6-异丙基-嘧啶-5-基)-2,2-二甲基-3,5-二氧六环-6-庚烯酸酯的方法
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CN102816152B (zh) * 2011-06-09 2015-09-09 上海京新生物医药有限公司 一种瑞苏伐他汀中间体的制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016065584A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine oxadiazole and thiadiazole orexin receptor antagonists
PE20240221A1 (es) 2016-06-16 2024-02-16 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN111518034A (zh) * 2019-10-21 2020-08-11 山东理工职业学院 他汀类化合物及其中间体的制备方法
CN112679490A (zh) * 2021-01-28 2021-04-20 安徽美诺华药物化学有限公司 瑞舒伐他汀钙含砜结构的手性侧链及其制备方法与用途

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4168267A (en) 1978-10-23 1979-09-18 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4405552A (en) 1981-03-03 1983-09-20 Eli Lilly And Company 1-Benzoyl-3-(arylphyridyl)urea compounds
US4432971A (en) 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4452790A (en) 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
ZA891696B (en) 1988-10-06 1990-11-28 Sandoz Ltd Pyrimidinyl-substituted hydroxyacids,lactones and esters and pharmaceutical compositions containing them
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US4933165A (en) 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
DE3929507A1 (de) 1989-09-06 1991-03-07 Bayer Ag Substituierte amino-pyridine
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
DE4022414A1 (de) 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
DE4023308A1 (de) 1990-07-21 1992-01-23 Bayer Ag Substituierte pyrido-oxazine
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
ES2106112T3 (es) 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5447954A (en) 1992-05-05 1995-09-05 Smithkline Beecham P.L.C. Phenylderivate as inhibitors of ATP citrate lyase
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HU223663B1 (hu) 1992-05-15 2004-11-29 Merrel Dow Pharmaceuticals Inc. Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
RU2124503C1 (ru) 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5712396A (en) 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
CZ292993B6 (cs) 1992-12-23 2004-01-14 Bristol-Myers Squibb Company Způsob přípravy taxanu nesoucího oxazolinový postranní řetězec a taxan tímto způsobem připravený
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5662934A (en) 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU717743B2 (en) 1995-12-13 2000-03-30 Regents Of The University Of California, The Nuclear receptor ligands and ligand binding domains
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US6537987B1 (en) 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CZ302475B6 (cs) 1997-10-08 2011-06-08 Sankyo Company Limited Substituované kumulované heterocyklické slouceniny
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
WO1999045913A1 (en) 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
HRP20000767A2 (en) 1998-05-12 2001-10-31 American Home Prod Benzothiophenes, benzofurans and indoles useful in the treatment of insulin resistance and hyperglycemia
JP2002514639A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション ナフト［２，３−ｂ］ヘテロアリー−４−イル誘導体
CN1308622A (zh) 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的联苯基氧代－乙酸
CN1308627A (zh) 1998-05-12 2001-08-15 美国家用产品公司 可用于治疗胰岛素抗性和高血糖的11－芳基－苯并[b]萘并[2,3－d]呋喃和11－芳基－苯并[b]萘并[2,3－d]噻吩
US6506785B2 (en) 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CA2334551A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000015201A2 (en) 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000030665A1 (en) 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
WO2000050574A1 (en) 1999-02-24 2000-08-31 Johns Hopkins University Compositions and methods for modulating serum cholesterol
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
HK1042480A1 (zh) 1999-06-15 2002-08-16 Bristol-Myers Squibb Pharma Company 取代的稠杂环γ-咔啉
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
CZ20022771A3 (cs) 2000-02-17 2003-09-17 Bristol-Myers Squibb Company Ligandy thyreoidního receptoru odvozené od anilinu
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
HUP0401724A2 (hu) 2001-06-06 2004-12-28 Bristol-Myers Squibb Co. Eljárás királis diol-szulfon és dihidroxi-sav típusú HMG CoA reduktáz inhibitorok előállítására
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors

Also Published As

Publication number Publication date
PE20050958A1 (es) 2005-11-17
EP1667997A1 (en) 2006-06-14
WO2005030758A1 (en) 2005-04-07
TW200522950A (en) 2005-07-16
US7371759B2 (en) 2008-05-13
US20050085497A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
AR045828A1 (es) Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa
AR028732A1 (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.
EP2613782A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
HRP20241674T1 (hr) 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
ECSP024384A (es) INHIBIDORES DE HMG - CoA REDUCTASA Y METODO
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
IN2014DN03063A (es)
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
AR085150A1 (es) Agentes moduladores de s1p
EA201200189A1 (ru) Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний
EA201071034A1 (ru) Новые макроциклические ингибиторы репликаций вируса гепатита с
AR074359A1 (es) Compuestos heterociclicos sustituidos como moduladores de canales ionicos
EA201001689A1 (ru) Производные спироиндола, предназначенные для лечения паразитарных заболеваний
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EP2032715A4 (en) METHOD AND MATERIALS FOR THE MANUFACTURE OF SIMVASTATIN AND RELATED COMPOUNDS
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
IN2015DN02966A (es)
RU2004139029A (ru) Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"

Legal Events

Date Code Title Description
FB Suspension of granting procedure